Navigation Links
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Date:3/2/2010

iologicals SA (GSK) for the development and commercialization of needle-free, patch-based vaccines. Under the terms of the agreement, GSK made an up-front cash contribution of EUR 33.6m (USD 49.4m), in addition to an equity investment of up to EUR 84.0m (USD 123.5m) through staggered share purchases of up to 5% of Intercell, of which 900,000 shares, or 1.9%, have been purchased in December 2009 at a price of EUR 31.21 per share.

With GSK as its future marketing partner, Intercell is pushing its development efforts for the investigational Travelers' Diarrhea (TD) Vaccine Patch towards licensure. The vaccine candidate targets an indication that affects approximately 20 million international travelers annually and for which no vaccine is currently available. The TD Vaccine Patch is presently being investigated in a randomized, placebo-controlled Phase III pivotal efficacy study of 1,800 travelers from Europe to Mexico and Guatemala. In addition, a Phase II placebo-controlled pilot-efficacy trial was launched in 800 subjects from the UK and Germany traveling to India as well as a recently initiated Phase II supportive safety study in healthy U.S. volunteers.

Vaccine Enhancement (VE) Patch - Pandemic Influenza p
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
2. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
3. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
4. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
5. Iomai Stockholders Approve Merger With Intercell Subsidiary
6. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
7. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™
8. Neogen Corporation Announces 3rd Quarter Results Conference Call
9. Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of ... results for the fourth quarter and full year ended ... Highlights(Compared to the fourth quarter 2013) , Quarterly ... from $22.9 million in the prior year period. Excluding ... vaccine of $0.1 million in the fourth quarter of ...
(Date:4/18/2015)... Aurigene and its partner ... presenting data at the poster sessions from two ... Annual Meeting (April 18-22 in Philadelphia, ... http://photos.prnewswire.com/prnh/20130418/608115 ) , Aurigene will present ... molecule inhibitors program, which is currently in preclinical ...
(Date:4/17/2015)... , April 17, 2015 /PRNewswire/ - SQI Diagnostics ... and diagnostics company that develops and commercializes proprietary ... today announced that it has received approval from ... of 5,126,044 outstanding common share purchase warrants ("the ... connection with the Company,s May 2013 private placement ...
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
Breaking Biology Technology:Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3
... , SPRINGFIELD, Ill., Dec. 1 ... that it was recently awarded two statuettes at the first-ever ... City. The CLIO Healthcare Awards recognizes creative excellence and innovation ... the CLIO Awards, one of the world,s most recognized awards ...
... ... Dynamics SL clients (including project accounting clients) to Synergy Business Solutions to maintain quality ... Seattle, ... the Microsoft Dynamics SL practice of Congruent Software, a Bellevue, WA business technology provider. ...
... , INDIANAPOLIS and NORTH VANCOUVER, British Columbia, Dec. ... The Dow Chemical Company (NYSE: DOW ), and ... and commercial license option agreement. The agreement provides Dow AgroSciences ... on an exclusive basis in major food crops, and on ...
Cached Biology Technology:Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 2Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 3
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... EDITOR,S PICK: SIRT(ain) benefit of reducing calories ... is reaching epidemic proportions. One of the main risk ... cells in the body (particularly liver, fat, and skeletal ... Substantially reducing caloric intake enhances the sensitivity of skeletal ...
... (MGH) researchers along with collaborators from Massachusetts ... have found a way to block, in an ... many disease conditions. In their report receiving ... the investigators describe using small interfering RNA technology ...
... in our body have a system that can handle ... underlying mechanism is called autophagy and literally means "self-eating". ... system and the increased release of building blocks equip ... render them resistant towards treatment. "We have ...
Cached Biology News:JCI online early table of contents: Oct. 10, 2011 2JCI online early table of contents: Oct. 10, 2011 3JCI online early table of contents: Oct. 10, 2011 4JCI online early table of contents: Oct. 10, 2011 5JCI online early table of contents: Oct. 10, 2011 6Novel technique uses RNA interference to block inflammation 2Small molecules can starve cancer cells 2
RAT ANTI RAT RT1Au (CLASS I POLYMORPHIC) Immunogen: AO lymphoid cells...
MOUSE ANTI HUMAN C-MYC aa171-188...
RABBIT ANTI NEOPTERIN...
... • Beagle serum is collected from fasted Beagle ... age Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate ... N-05: ACD N-07: CPD ...
Biology Products: